101 related articles for article (PubMed ID: 16414297)
1. Airway blood flow reactivity in smokers.
Wanner A; Campos MA; Mendes E
Pulm Pharmacol Ther; 2007; 20(2):126-9. PubMed ID: 16414297
[TBL] [Abstract][Full Text] [Related]
2. Airway blood flow reactivity in healthy smokers and in ex-smokers with or without COPD.
Mendes ES; Campos MA; Wanner A
Chest; 2006 Apr; 129(4):893-8. PubMed ID: 16608935
[TBL] [Abstract][Full Text] [Related]
3. Effect of an inhaled glucocorticoid on endothelial function in healthy smokers.
Mendes ES; Horvath G; Rebolledo P; Monzon ME; Casalino-Matsuda SM; Wanner A
J Appl Physiol (1985); 2008 Jul; 105(1):54-7. PubMed ID: 18467553
[TBL] [Abstract][Full Text] [Related]
4. Airway vascular endothelial function in healthy smokers without systemic endothelial dysfunction.
Mendes ES; Cancado JED; Rebolledo P; Arana J; Parker M; Gonzalez A; Hurwitz BE; Wanner A
Chest; 2013 Jun; 143(6):1733-1739. PubMed ID: 23348843
[TBL] [Abstract][Full Text] [Related]
5. Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma.
Mendes ES; Horvath G; Campos M; Wanner A
J Allergy Clin Immunol; 2008 Mar; 121(3):700-4. PubMed ID: 18086493
[TBL] [Abstract][Full Text] [Related]
6. Airway and Pulmonary β
Hurwitz BE; Mendes ES; Schmid A; Parker M; Arana J; Gonzalez A; Wanner A
Chest; 2017 Mar; 151(3):650-657. PubMed ID: 28012803
[TBL] [Abstract][Full Text] [Related]
7. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD.
Kim WJ; Sheen SS; Kim TH; Huh JW; Lee JH; Kim EK; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Oh YM; Lee SD
Respirology; 2009 Mar; 14(2):260-3. PubMed ID: 19210659
[TBL] [Abstract][Full Text] [Related]
8. Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma.
Brieva JL; Danta I; Wanner A
Am J Respir Crit Care Med; 2000 Jan; 161(1):293-6. PubMed ID: 10619834
[TBL] [Abstract][Full Text] [Related]
9. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
10. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease.
Zietkowski Z; Kucharewicz I; Bodzenta-Lukaszyk A
Respir Med; 2005 Jul; 99(7):816-24. PubMed ID: 15939243
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
[TBL] [Abstract][Full Text] [Related]
12. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
Terzano C; Petroianni A; Ricci A; Allegra L
Eur Rev Med Pharmacol Sci; 2005; 9(4):209-15. PubMed ID: 16128040
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
15. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.
Kunisaki KM; Rice KL; Janoff EN; Rector TS; Niewoehner DE
Ther Adv Respir Dis; 2008 Apr; 2(2):55-64. PubMed ID: 19124359
[TBL] [Abstract][Full Text] [Related]
16. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD.
Leivo-Korpela S; Lehtimäki L; Vuolteenaho K; Nieminen R; Kööbi L; Järvenpää R; Kankaanranta H; Saarelainen S; Moilanen E
Respir Med; 2014 Jan; 108(1):122-8. PubMed ID: 24135487
[TBL] [Abstract][Full Text] [Related]
18. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK;
Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444
[TBL] [Abstract][Full Text] [Related]
19. Changes in oscillatory impedance and nitrogen washout with combination fluticasone/salmeterol therapy in COPD.
Timmins SC; Diba C; Schoeffel RE; Salome CM; King GG; Thamrin C
Respir Med; 2014 Feb; 108(2):344-50. PubMed ID: 24144670
[TBL] [Abstract][Full Text] [Related]
20. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
